Funding profile · Neuropsychiatric therapeutics
Gilgamesh Pharmaceuticals
Seven Form D filings under the original company, four under the 2025 spinout, and three single company vehicles formed around one round.
$60.0MSeries A of Gilgamesh Pharma Inc., offered and sold in full, Form D filed Mar 24, 2026
$66.1MNew equity sold by the spinout in 2026, across two filings
$1.20BCeiling on the AbbVie purchase of bretisilocin, Aug 2025
$3.59MNIDA funds obligated against a grant announced as $14 million
Data as of September 22, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Apr 2020 | Seed, equity and debt | $2,434,845 sold | 25 | Form D |
| Jul to Sep 2020 | Two note offerings around YC | $150,000 and $735,000 | 1, then 10 | Form D |
| Apr 2021 | Series A | $34,701,837 of $34,701,891 | 66 | Form D |
| May to Dec 2022 | Series B, announced at $39M | $13,761,009 of $50,000,001 at filing | 14 at filing; Prime Movers Lab lead | Form D and release |
| May 2024 | AbbVie option to license | $65,000,000 upfront, up to $1.95B | AbbVie | Partner release |
| Aug 2025 | AbbVie buys bretisilocin; rest spun out | Up to $1,200,000,000 | AbbVie | Partner release |
| Jan 2026 | Spinout equity, not announced | $6,090,946 sold in full | 9 | Form D |
| Mar 2026 | Series A of Gilgamesh Pharma Inc. | $60,000,000 sold in full | 40; Satori Neuro lead | Form D and release |
| 2024 to 2025 | NIDA award UG3DA060053 | $3,588,425 obligated | NIDA | NIH RePORTER |
What the filings show
Gilgamesh Pharma Inc. · Form D · filed Mar 24, 2026
- First sale
- Mar 9, 2026
- Security
- Preferred stock
- Offered
- $60,000,000
- Sold
- $60,000,000 · nothing remaining
- Investors
- 40 · average $1,500,000
- Minimum
- $50,000 · Rule 506(b)
- Related persons
- Jonathan Sporn and Andrew Kruegel (officers and directors); Amy Kruse, Zia Huque, Phil Skolnick, Robert Berman (directors)
- Filing
- SEC EDGAR, CIK 0002107396
Gilgamesh Pharma Inc. · Form D · filed Feb 4, 2026
- First sale
- Jan 2, 2026
- Offered and sold
- $6,090,946 equity, nothing remaining
- Investors
- 9 · average about $676,800
- Companion filing
- A second Form D the same day covering $4,366,118 of employee options, none exercised, 8 recipients
- Filing
- SEC EDGAR, CIK 0002107396
Gilgamesh Pharmaceuticals, Inc. · Form D · filed May 19, 2022
- First sale
- May 16, 2022
- Offered
- $50,000,001
- Sold
- $13,761,009 · $36,238,992 remaining
- Investors
- 14 · average about $982,900
- Exemption
- Rule 506(c), which permits general solicitation. Every other Gilgamesh filing uses 506(b)
- Filing
- SEC EDGAR, CIK 0001817048. No later filing under this CIK
Three single company vehicles · Feb and Mar 2026
- PML SPV 1 LP
- Filed Feb 20, 2026. Indefinite offering, nothing sold at filing. General partner Prime Movers Lab GP IV LLC
- What If Ventures series
- Filed Mar 18, 2026. $1,770,500 sold in full, 25 investors, average $70,820. Sydecar administers
- TL Capital series
- Filed Mar 23, amended Mar 26, 2026. $1,835,950 sold in full, 13 investors. Sydecar administers
- Combined
- $3,606,450 from 38 investors, about 6 percent of the announced round
Reading the filings
- The Series A is closed, not a target.$60,000,000 offered and $60,000,000 sold, nothing remaining, 40 investors, $1,500,000 each on average. The Form D was filed on March 24, 2026, the same day as the press release. An offering that lands filed and full on announcement day was papered before the news went out.
- The headline understates the new equity.The spinout had already sold $6,090,946 to 9 investors, first sale January 2, 2026. Adding that to the Series A gives $66,090,946 for the year. Forbes reported in September 2026 that Gilgamesh raised “another $70 million afterwards”; the filings account for about $66.1 million of it, and the January tranche was never announced.
- Angels reached the round through Sydecar.Two series vehicles, one named for What If Ventures and one for TL Capital, pooled $3,606,450 from 38 people at an average of about $94,900, and appear in the company filing as two of the 40 investors. A Prime Movers Lab vehicle filed a month earlier with nothing sold, the usual sequence for a fund assembling an allocation.
- The old company stopped filing while the announcements continued.The last Form D under CIK 0001817048 reports $13,761,009 sold of $50,000,001 as of May 19, 2022. Seven months later the company announced a closed $39 million Series B. No amendment was filed. Pharmaphorum likewise called the 2021 round a $27 million Series A while the Form D reports $34,701,837 from 66 investors.
- The lead investor has been a director for five years.Sporn, Kruegel, Amy Kruse, Phil Skolnick and Robert Berman appear on both the 2022 and 2026 filings. Gaetano Crupi is gone and Zia Huque is new. Kruse joined the board in 2021 from Prime Movers Lab and led the 2026 round from Satori Neuro.
- The non-dilutive figure needs a footnote.A $14 million NIDA grant was announced in March 2024. RePORTER shows $2,747,151 obligated in FY2024 and $841,274 in FY2025 on UG3DA060053, a total of $3,588,425. The remainder sits in a later phase released only on milestones.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Revenue | None. Funded by financings, one asset sale, one option deal and one federal grant. | Independent |
| Realized value | Bretisilocin sold to AbbVie August 2025 for up to $1.2 billion. Upfront and milestone split not disclosed. | Partner-stated |
| Partnered program | AbbVie neuroplastogen option, $65 million paid May 2024, up to $1.95 billion in aggregate, transferred to the spinout. | Partner-stated |
| Clinical status | Two completed Phase 2a studies. No FDA approval, no 510(k), no PMA. | Public record |
| Headcount | 15 per the Y Combinator profile, 16 per Lucid News in 2023. Chemistry is outsourced. | Company-stated |
What to watch
- An amended Form D on the March 2026 offering, which would show sales above $60,000,000.
- Whether the $15,000,000 option pool filed March 31, 2026 fills out. Only $2,250,000 had been taken by 3 recipients.
- The later phase of UG3DA060053, against a $14 million announcement.
- Milestone payments from AbbVie, which would arrive without any Form D.
The Gilgamesh Pharmaceuticals story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordForm D filings, Gilgamesh Pharmaceuticals, Inc., CIK 0001817048
- Public recordForm D filings, Gilgamesh Pharma Inc., CIK 0002107396
- Public recordForm D, Gilgamesh Pharma PML SPV 1 LP, CIK 0002112386
- Public recordForm D, Gilgamesh Pharma a Series of What If Ventures Master LLC, CIK 0002117043
- Public recordForm D and D/A, Gilgamesh TL Capital a Series of CGF2021 LLC, CIK 0002122848
- Public recordNIH RePORTER, UG3DA060053
- IndependentHow Gilgamesh Turned On Big Pharma’s Billion-Dollar Appetite For Psychedelic Drugs
- IndependentAbbVie takes option on Gilgamesh CNS drugs in $2bn deal
- CompanyGilgamesh Pharmaceuticals Raises $39 Million Series B
- CompanyGilgamesh Pharma Closes Oversubscribed $60 Million Series A
- PartnerAbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin
Compiled from SEC, NIH and ClinicalTrials.gov public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Gilgamesh Pharmaceuticals. This page is not an offer to sell or a recommendation to buy any security.